Support Alert

COVID-19 Therapeutic Alert-casirivimab and imdevimab in the treatment of COVID-19 in hospitalised patients

NHS access to the combination monoclonal antibody casirivimab plus imdevimab (marketed as Ronapreve®) has been extended in patients aged 12 and above and should now be considered at a total dose of 2.4g in COVID positive antibody seronegative patients who have been hospitalised specifically to manage the symptoms of COVID infection. A dose of 1.2g in patients who are admitted to hospital for another (non COVID-related) indication but nonetheless test positive during their hospital stay and are either at high risk of disease progression or COVID infection is considered to be likely to destabilise their existing medical condition or compromise recovery from their hospital procedure. 

Further details of the recommendations can be found in the COVID-19 Therapeutic Alert



Renew for 2022

Your dedication to patient care has made us proud during 2021.

That's why you can count on us to represent your interests and support your efforts every step of the way in 2022.